drugset / Trial / NCT04717700
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
Phase 2
Active not recruiting
50 enrolled
Ida Bruun Kristensen
Karyopharm Therapeutics Inc · collabOdense Patient Data Explorative Network · collab
NaSingle-groupOpen-labelTreatment
Summary
An unrandomized phase 2 study of selinexor in combination with lenalidomide/ bortezomib and dexamethasone to newly diagnosed, transplant in-eligible symptomatic multiple myeloma patients in a multicenter international set-up within the Nordic Multiple Myeloma Study Group
Timeline
- Start
- 2021-08-18
- Primary completion
- 2025-08-01
- Completion
- 2029-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |
| Background | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |
| Background | Lenalidomide | Other / unclassified | 25 mg | Oral |